- Exchange: NASDAQ CM
- Sector: Health Care
- Industry: Medical Equipment/Devices
- Sub-Industry: Health Care Supplies
Delcath Systems Inc
+ Add to WatchlistDCTH:US
0.5102 USD 0.0797 13.51%As of 11:32:27 ET on 10/03/2013.
Snapshot for Delcath Systems Inc (DCTH)
| Open: | 0.5800 | Day's Range: | 0.4826 - 0.5800 | Volume: | 9,160,770 |
|---|---|---|---|---|---|
| Previous Close: | 0.5899 | 52wk Range: | 0.2913 - 2.3800 | 1-Yr Rtn: | -71.23% |
Key Statistics for DCTH
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.5300 |
| Est. EPS (USD) (12/2013) | -0.3700 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 51.91 |
| Shares Outstanding (M) | 101.56 |
| 30 Day Average Volume | 3,184,250 |
| Price/Book (mrq) | 1.5103 |
| Price/Sale (ttm) | 66.6651 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Dividend Ex-Date | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 11/07/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for DCTH
Company Profile & Key Executives for DCTH
Delcath Systems Inc. has developed a system to isolate the liver from the circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver. This system filters the patients blood removing most of the harmful chemotherapy agents lessening the side-effects of the treatment.
| Gabriel Leung "Gabe"Chairman | Jennifer SimpsonInterim Co-Pres & Co- CEO/Exec VP |
| Graham G MiaoInterim Co-Pres & Co-CEO/CFO | Peter James GrahamExec VP/Chief Compliance Ofcr |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
Advertisement
-
DCTH News
-
Industry News
Advertisement
Sponsored Links
Advertisements
Rate this Page